Francisca E. Cara

606 total citations
15 papers, 387 citations indexed

About

Francisca E. Cara is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Francisca E. Cara has authored 15 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Francisca E. Cara's work include Cancer Cells and Metastasis (3 papers), Graphene and Nanomaterials Applications (2 papers) and Mechanisms of cancer metastasis (2 papers). Francisca E. Cara is often cited by papers focused on Cancer Cells and Metastasis (3 papers), Graphene and Nanomaterials Applications (2 papers) and Mechanisms of cancer metastasis (2 papers). Francisca E. Cara collaborates with scholars based in Spain, Mexico and United States. Francisca E. Cara's co-authors include Sergio Granados‐Principal, José A. Lorente, Mauro Ferrari, Pedro Sánchez‐Rovira, Juan Antonio Marchal, Elvin Blanco, Suhong Wu, Víctor Segura-Ibarra, Guillermo U. Ruiz‐Esparza and Carmen Griñán‐Lisón and has published in prestigious journals such as Advanced Functional Materials, Oncogene and Journal of Controlled Release.

In The Last Decade

Francisca E. Cara

14 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francisca E. Cara Spain	11	159	70	66	64	53	15	387
Vino T. Cheriyan United States	13	277 1.7×	106 1.5×	57 0.9×	57 0.9×	53 1.0×	22	492
Vinod Balachandran India	12	315 2.0×	130 1.9×	38 0.6×	71 1.1×	48 0.9×	14	598
Dandan Jiang China	13	240 1.5×	78 1.1×	98 1.5×	56 0.9×	20 0.4×	29	449
Arvind Thakkar United States	15	275 1.7×	106 1.5×	53 0.8×	127 2.0×	44 0.8×	22	544
Sachin Bagde India	2	179 1.1×	50 0.7×	66 1.0×	29 0.5×	34 0.6×	5	509
Chunlei Xu China	15	219 1.4×	66 0.9×	62 0.9×	62 1.0×	54 1.0×	53	748
Chiara Ullio Italy	9	300 1.9×	55 0.8×	32 0.5×	40 0.6×	23 0.4×	10	508
Élisabeth Miot-Noirault France	10	157 1.0×	69 1.0×	41 0.6×	23 0.4×	46 0.9×	15	368
Xiang‐Dong Yan United States	9	206 1.3×	80 1.1×	46 0.7×	43 0.7×	46 0.9×	14	538

Countries citing papers authored by Francisca E. Cara

Since Specialization

Citations

This map shows the geographic impact of Francisca E. Cara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisca E. Cara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisca E. Cara more than expected).

Fields of papers citing papers by Francisca E. Cara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisca E. Cara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisca E. Cara. The network helps show where Francisca E. Cara may publish in the future.

Co-authorship network of co-authors of Francisca E. Cara

This figure shows the co-authorship network connecting the top 25 collaborators of Francisca E. Cara. A scholar is included among the top collaborators of Francisca E. Cara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisca E. Cara. Francisca E. Cara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Cara, Francisca E., César L. Ramírez-Tortosa, Ana Sánchez, et al.. (2025). Signature-based repurposed drugs resemble the inhibition of TGFβ-induced NDRG1 as potential therapeutics for triple-negative breast cancer. International Journal of Biological Sciences. 21(9). 3949–3967.

Frejo, Lidia, et al.. (2024). Allergy and autoinflammation drive persistent systemic inflammatory response in Meniere Disease: A longitudinal study. Clinical Immunology. 271. 110413–110413. 9 indexed citations

López-Onieva, Lourdes, Jordi Martorell‐Marugán, Carmen Griñán‐Lisón, et al.. (2022). EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization. Oncogene. 41(28). 3611–3624. 18 indexed citations

Griñán‐Lisón, Carmen, et al.. (2022). TGFβ Governs the Pleiotropic Activity of NDRG1 in Triple-Negative Breast Cancer Progression. International Journal of Biological Sciences. 19(1). 204–224. 6 indexed citations

Sánchez‐Martín, Rosario M., Marı́a J. Garrido, Carmen Griñán‐Lisón, et al.. (2022). Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer. Pharmaceutics. 14(3). 505–505. 9 indexed citations

Griñán‐Lisón, Carmen, et al.. (2021). Antioxidants for the Treatment of Breast Cancer: Are We There Yet?. Antioxidants. 10(2). 205–205. 56 indexed citations

Ayllón, Verónica, Pedro Carmona‐Sáez, Verónica Ramos–Mejía, et al.. (2020). GARP is a key molecule for mesenchymal stromal cell responses to TGF-β and fundamental to control mitochondrial ROS levels. Stem Cells Translational Medicine. 9(5). 636–650. 12 indexed citations

Cara, Francisca E., et al.. (2020). Drug Repurposing for Triple-Negative Breast Cancer. Journal of Personalized Medicine. 10(4). 200–200. 26 indexed citations

Marchal, Juan Antonio, Francisca E. Cara, Anthony M.C. Brown, et al.. (2018). Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways. European Journal of Nutrition. 58(8). 3207–3219. 48 indexed citations

10.

Pulido‐Moran, Mario, César L. Ramírez-Tortosa, José L. Quiles, et al.. (2018). Modulation by hydroxytyrosol of oxidative stress and antitumor activities of paclitaxel in breast cancer. European Journal of Nutrition. 58(3). 1203–1211. 42 indexed citations

11.

Segura-Ibarra, Víctor, A.S. Cruz-Solbes, Francisca E. Cara, et al.. (2017). Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension. International Journal of Pharmaceutics. 524(1-2). 257–267. 26 indexed citations

12.

Segura-Ibarra, Víctor, Francisca E. Cara, Suhong Wu, et al.. (2017). Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention. Journal of Controlled Release. 262. 18–27. 15 indexed citations

13.

Ruiz‐Esparza, Guillermo U., Víctor Segura-Ibarra, Andrea M. Cordero‐Reyes, et al.. (2016). A Specifically Designed Nanoconstruct Associates, Internalizes, Traffics in Cardiovascular Cells, and Accumulates in Failing Myocardium: A New Strategy for Heart Failure Diagnostics and Therapeutics. European Journal of Heart Failure. 18(2). 169–178. 33 indexed citations

14.

Blanco, Elvin, Takafumi Sangai, Suhong Wu, et al.. (2014). Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Molecular Therapy. 22(7). 1310–1319. 55 indexed citations

15.

Ruiz‐Esparza, Guillermo U., Suhong Wu, Víctor Segura-Ibarra, et al.. (2014). Polymer Nanoparticles Encased in a Cyclodextrin Complex Shell for Potential Site‐ and Sequence‐Specific Drug Release. Advanced Functional Materials. 24(30). 4753–4761. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact